<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: B cells play a central role in <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="1" pm="."><plain>Rituximab is expected to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of <z:hpo ids='HP_0000001'>all</z:hpo> the CD20-positive B cells </plain></SENT>
<SENT sid="2" pm="."><plain>A proportion of patients are refractory or intolerant to standard immunosuppression </plain></SENT>
<SENT sid="3" pm="."><plain>These are candidate to new therapeutic options </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Eight patients [six women, two men, mean age 41-year-old (27-51), with severe multiorgan involvement (kidney, skin, <z:mp ids='MP_0008912'>nervous</z:mp> system, <z:e sem="disease" ids="C0162323" disease_type="Disease or Syndrome" abbrv="">polyarthritis</z:e>, <z:e sem="disease" ids="C0151859" disease_type="Disease or Syndrome" abbrv="">polyserositis</z:e>, <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome)] were considered eligible for an intensive combination therapy including rituximab </plain></SENT>
<SENT sid="5" pm="."><plain>Rituximab was administered (dose 375 mg/m(2)) on Days #2, 8, 15 and 22 </plain></SENT>
<SENT sid="6" pm="."><plain>Two more doses were administered 1 and 2 months following the last weekly infusion </plain></SENT>
<SENT sid="7" pm="."><plain>This treatment was combined with two pulses of 750 mg <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (Days #4 and 17) and three pulses of 15 mg/kg (Days #1, 4 and 8) <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> followed by oral <z:chebi fb="0" ids="8382">prednisone</z:chebi>, 50 mg for 2 weeks rapidly tapered until 5 mg in 2 months </plain></SENT>
<SENT sid="8" pm="."><plain>Response was evaluated by assessing the changes in clinical signs and symptoms [<z:hpo ids='HP_0002725'>Systemic Lupus Erythematosus</z:hpo> Disease Activity Index (SLEDAI score)] and laboratory parameters for at least 12 months </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Levels of erythrocyte sedimentation rate and anti-double-strand DNA antibodies significantly decreased (P &lt; 0.01 at 12 months), whereas C3 and mainly C4 values increased at 6 months (P &lt; 0.01 for C4) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000093'>Proteinuria</z:hpo> improved in the cases with renal involvement (P &lt; 0.01 at 3, 6 and 12 months) </plain></SENT>
<SENT sid="11" pm="."><plain>SLEDAI score improved moving from the mean 17.3 (12-27) before therapy to 3.1 (1-5) after rituximab treatment </plain></SENT>
<SENT sid="12" pm="."><plain>Constitutional symptoms including <z:hpo ids='HP_0002829'>arthralgia</z:hpo>, <z:mp ids='MP_0000746'>weakness</z:mp> and <z:hpo ids='HP_0001945'>fever</z:hpo> disappeared in <z:hpo ids='HP_0000001'>all</z:hpo> the previously affected patients; <z:hpo ids='HP_0003401'>paresthesia</z:hpo> improved in the four patients with <z:hpo ids='HP_0001271'>polyneuropathy</z:hpo> and <z:mp ids='MP_0001212'>skin lesions</z:mp> gradually resolved in the patients with necrotizing <z:hpo ids='HP_0200042'>skin ulcers</z:hpo> at presentation </plain></SENT>
<SENT sid="13" pm="."><plain>Drug side effects were negligible </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Long-lasting remissions were obtained in patients with severe SLE and major organ involvement by this intensive administration of rituximab combined with low doses of intravenous <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> pulses followed by a rapid tapering of <z:chebi fb="0" ids="8382">prednisone</z:chebi> to 5 mg/day as a sole maintenance therapy </plain></SENT>
</text></document>